Sign in
CompletedPhase 2

Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)

Key facts

Who runs it
VA Office of Research and Development
Where
San Francisco and Tuscaloosa, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
39 people enrolled
Started
15 Oct 2022
Ended
31 Jul 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • CORT108297
  • Placebo
Record updated
27 October 2026

Who can take part

Age
18 years to 69 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • History of US military service
  • Capable of reading and understanding English
  • Able to provide written informed consent
  • Symptoms of post-traumatic stress disorder (must score 23 or greater on the CAPS-5 assessment at screening visit)
  • Men and pre-menopausal women must agree to use two forms of reliable contraception, one of which is a barrier method
  • Participants who use an SSRI or SNRI medication for PTSD must be on a stable dose for 8 weeks before enrollment
  • Participants who use trazodone for sleep must be on a stable dose
  • Participants who use opiate pain medication must be on a stable dose
  • For participants who are in psychotherapy, treatment must be stable for 6 weeks

Who cannot take part

  • Currently using certain antidepressant medications such as doxepin or tricyclics
  • Currently using certain mood stabilizers, such as lithium
  • Currently using antipsychotic medication
  • Currently using corticosteroid medication (oral or inhaled)
  • Use of certain medications that can interfere with the effects of the study drug
  • High blood pressure that is not controlled by medication
  • Alcohol use that meets criteria for Alcohol Use Disorder in past 3 months
  • Marijuana or other drug use that meets criteria for Substance Use Disorder in past 3 months
  • Ever diagnosed with: Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Obsessive-Compulsive Disorder, or Major Depressive Disorder with Psychotic Features
  • History of neurological disease
  • Angina, congestive heart failure or low blood pressure
  • Heart attack in the past 6 months
  • Heart block or irregular heartbeat
  • Kidney failure, liver failure or pancreatitis
  • Severe chronic obstructive pulmonary disease (COPD)
  • Use of certain medications that can affect heart rhythm
  • Diabetes that is not well-controlled
  • History of certain types of head injuries
  • Mild cognitive impairment
  • History of liver disease with lab results on AST or ALT more than 2 times the normal readings
  • History of kidney disease with lab results on eGFR less than 60 ml/min
  • History of additional risk factors for Torsades de pointes, such as heart failure, low potassium, or family history of a heart rhythm disorder called long QT syndrome
  • Experienced any psychologically traumatic event in the past 3 months
  • High risk for suicide or violent behavior
  • Has sleep apnea and not using any treatment, such as continuous positive airway pressure (CPAP)

Where in United States

  • San Francisco VA Medical Center, San Francisco, CASan Francisco, United States
  • Tuscaloosa VA Medical Center, Tuscaloosa, ALTuscaloosa, United States

About the trial

What the trial wants to find out

The purpose of this study is to test the drug CORT108297, which blocks the hormone cortisol, for treatment of PTSD in Veterans, and establish a safety profile that will inform the design of future studies.

The 2 groups in the trial

  • CORT108297Treatment being tested

    CORT108297- 180 milligrams (mg) daily for 7 days

  • PlaceboPlacebo, for comparison

    Placebo- 180 milligrams (mg) daily for 7 days

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD)
Record updated
27 October 2026